The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Renvela sevelamer carbonate | Sanofi Winthrop Industrie | Hyperphosphatemia; Renal Dialysis | 🇪🇺 EU 2009-06-09 | Order → |
| ellaOne ulipristal acetate | Laboratoire HRA Pharma | Contraception, Postcoital | 🇪🇺 EU 2009-05-15 | Order → |
| Modigraf tacrolimus | Astellas Pharma Europe B.V. | Graft Rejection | 🇪🇺 EU 2009-05-15 | Order → |
| Qutenza capsaicin | Grunenthal GmbH | Neuralgia | 🇪🇺 EU 2009-05-15 | Order → |
| Nimvastid rivastigmine Generic | KRKA tovarna zdravil d.d. Novo mesto | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 2009-05-11 | Order → |
| Exalief eslicarbazepine acetate | BIAL - Portela Ca, S.A. | Epilepsy | 🇪🇺 EU 2009-04-21 | Order → |
| Zebinix eslicarbazepine acetate | BIAL - Portela & Ca, S.A. | Epilepsy | 🇪🇺 EU 2009-04-21 | Order → |
| Removab catumaxomab | Neovii Biotech GmbH | Ascites; Cancer | 🇪🇺 EU 2009-04-20 | Order → |
| Conbriza bazedoxifene | Pfizer Europe MA EEIG | Osteoporosis, Postmenopausal | 🇪🇺 EU 2009-04-17 | Order → |
| Rivastigmine Teva rivastigmine Generic | Teva Pharma B.V. | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 2009-04-17 | Order → |
| Ixiaro Japanese encephalitis vaccine (inactivated, adsorbed) | Valneva Austria GmbH | Encephalitis, Japanese; Immunization | 🇪🇺 EU 2009-03-31 | Order → |
| Ribavirin Teva ribavirin Generic | Teva B.V. | Hepatitis C, Chronic | 🇪🇺 EU 2009-03-31 | Order → |
| Synflorix pneumococcal polysaccharide conjugate vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Pneumococcal Infections; Immunization | 🇪🇺 EU 2009-03-29 | Order → |
| Fertavid follitropin beta | Merck Sharp & Dohme B.V. | Infertility; Hypogonadism | 🇪🇺 EU 2009-03-19 | Order → |
| Mepact mifamurtide | Esteve Pharmaceuticals, S.A. | Osteosarcoma | 🇪🇺 EU 2009-03-06 | Order → |
| Celvapan influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated) | Nanotherapeutics Bohumil, s.r.o. | Disease Outbreaks; Influenza, Human; Immunization | 🇪🇺 EU 2009-03-04 | Order → |
| Efient prasugrel | Substipharm | Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction | 🇪🇺 EU 2009-02-24 | Order → |
| Fablyn lasofoxifene | Dr. Friedrich Eberth Arzneimittel GmbH | Osteoporosis, Postmenopausal | 🇪🇺 EU 2009-02-24 | Order → |
| IDflu influenza vaccine (split virion, inactivated) | Sanofi Pasteur S.A. | Influenza, Human; Immunization | 🇪🇺 EU 2009-02-24 | Order → |
| Intanza influenza vaccine (split virion, inactivated) | Sanofi Pasteur Europe | Influenza, Human; Immunization | 🇪🇺 EU 2009-02-24 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.